October 28, 2017 | New Delhi, IndiaStrand Life Sciences, one of India’s foremost bioinformatics and genomic profiling firms, has launched the “Spread Pink. Spread Courage.” campaign this October to raise awareness around Breast Cancer and to commemorate the Breast Cancer Awareness Month. As a part of this campaign, the...
Extension of CAP accreditation following a recent inspection of Strand Centre for Genomics and Personalized Medicine Lab in Bangalore November 21, 2017 | Bangalore, IndiaStrand Life Sciences, India’s leading genomic profiling and bioinformatics company, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP), an...
Strand Life Sciences today released the findings of their study on Hereditary Breast and Ovarian Cancer Cases in India – Study highlights that BRCA gene mutations are the primary cause of Hereditary Breast and Ovarian Cancer in IndiaJuly 14, 2017 | Bangalore, IndiaStrand Life Sciences, a leader in precision medicine...
Strand LB helps monitor lung, breast, colorectal and other cancers for tumor presence, response, and recurrenceApril 11, 2017 | Bangalore, IndiaAccording to data from the Indian Council of Medical Research (ICMR), India is projected to have 17.3 lakhs new cases of cancer reported in 2020 and over 8.8 lakhs...
Strategic initiative creates integrated platform dedicated to next generation precision medicine January 4, 2018 | Bengaluru, India Healthcare Global Enterprises, Ltd. (HCG:NSE) today announced execution of definitive agreements for the business combination of its Triesta Sciences business unit (“Triesta”) with Strand Life Sciences Pvt. Ltd. (“Strand”). Strand, established in 2000 as a...
February 8, 2018 | Bangalore Strand Life Sciences announced an investment by Quadria Capital, Asia’s leading healthcare focused private equity investor. India-based HealthQuad Fund and Singapore-based Heritas Venture Fund also contributed to this fund. Strand Life Sciences, formed from the business combination of Strand and Triesta, the diagnostics unit of HCG,...
A study conducted by Strand Life Sciences shows that in the Indian population, there is a high prevalence of germline mutations in the BRCA1, BRCA2, TP53 and PALB2 genes March 13, 2018 | Bangalore Strand Life Sciences, a leader in precision medicine diagnostics committed to empowering cancer and inherited disease care in India today released the findings...
October 6, 2018 | Bangalore Strand Life Sciences announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics, the world’s leading provider of diagnostic information services. “This acquisition is an important addition to our network of 24 diagnostic labs across India, especially as we continue to expand our...
